{
    "nctId": "NCT01104571",
    "briefTitle": "Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer",
    "officialTitle": "Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 257,
    "primaryOutcomeMeasure": "Increase in apoptosis, by change in the tumor (morphological apoptosis and activated caspase 3) measured at diagnosis and at surgery (biological phase)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed (by core biopsy) invasive breast cancer\n\n  * Newly diagnosed disease\n  * Resectable disease\n* HER2-positive disease, defined as 3+ measured by IHC or gene amplification by fluorescent in situ hybridization (FISH)\n* No evidence of metastatic disease (T4 category) or suspicion of distant metastases\n* No inflammatory breast cancer\n* Planned surgery within 1 month of diagnosis, and willing to undergo adjuvant chemotherapy and trastuzumab post-surgery\n* Must consent to donation of tissue and blood samples\n* Hormone receptor status known\n\n  * Estrogen receptor-positive patients on hormone replacement therapy (HRT) must either continue HRT or must not have taken HRT within the past 3 weeks\n  * Estrogen receptor-negative patients may enter the trial whether or not they have taken HRT within the past 3 weeks\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%\n* Serum creatinine \\< 2 times upper limit of normal (ULN) OR creatinine clearance \\> 30 mg/dL\n* Bilirubin \\< 2 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective non-hormonal contraception\n* LVEF \u2265 55% by echocardiography or MUGA\n* No clinically significant cardiac abnormalities or uncontrolled hypertension\n* No prior myocardial infarction, heart failure, or significant angina\n* No prior cancer at any other site that has been treated within the past 6 months (except basal cell carcinoma or cervical carcinoma in situ)\n* No current active hepatic or biliary disease (except Gilbert syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease, per investigator assessment)\n* No impaired gastrointestinal function that would sufficiently reduce lapatinib ditosylate absorption\n* No known immediate or delayed hypersensitivity or reaction to drugs chemically related to trastuzumab or lapatinib ditosylate\n* No altered mental state that would preclude obtaining written informed consent\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior trastuzumab (Herceptin\u00ae) therapy within the past 3 months\n* No prior local cancer treatment (e.g., radiotherapy)\n* No other concurrent investigational agent or anticancer therapy\n* No use of herbal (alternative) therapies within 1 day of study entry (vitamin and/or mineral supplements allowed)\n* No regular use of systemic steroids or other agents that could influence study endpoints (inhaled steroids allowed)\n* No grapefruit and grapefruit juice for the duration of the study\n* At least 14 days since prior and no concurrent CYP3A4 inducers\n* At least 7 days since prior and no concurrent CYP3A4 inhibitors\n* At least 6 months since prior and no concurrent amiodarone",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}